Red Arrow Therapeutics closes $4.5M Seed Extension funding to advance pH-sensing nanomedicine drug delivery technologies

Apr 23, 2024•over 1 year ago

Amount Raised

$4.5 Million

Round Type

seed

CambridgeTherapeuticsBiotechnologyHealth Care

Investors

Osaka University Venture Capital Co., Ltd.Keio Innovation Initiative, Inc.The University Of Tokyo Edge Capital Partners Co., Ltd.Beyond Next Ventures Inc.

Description

Red Arrow Therapeutics Inc., a developer of pH-sensing nanomedicine drug delivery technologies, closed a $4.5M Seed Extension round. The funding will be used to obtain key preclinical data on safety and efficacy of their lead compound, IL-12-loaded nanopolymeric micelles, and enable manufacturing initiation in collaboration with external partners.

Company Information

Company

Red Arrow Therapeutics

Location

Cambridge, Massachusetts, United States

About

Red Arrow Therapeutics, Inc. is a biotechnology company focusing on developing new technologies that can turn "cold" tumors into inflamed "hot" tumors. Red Arrow Therapeutics' lead product candidate, RA-001, a pH-activated polymer micelle loaded with IL-12, is designed to release fully active IL-12 upon sensing intratumoral pH to safely potentiate immunotherapy. In the current pre-clinical data, RA-001 exhibits strong anti-tumor immunity in various tumor models. Furthermore, RA-001 shows high efficacy as monotherapy and in combination with immune checkpoint inhibitors.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns